Acne vulgaris affects 80% of young adults; can induce permanent disfigurement 

The mainstay of therapeutics consist of eradicating C. acnes and reducing inflammation; however, treatment has been associated with the emergence of antibiotic resistance

Resistance to two first line antibiotics, clindamycin and erythromycin, currently stands at 30-50%

Blue light LED devices (outside the 410-430nm range) and benzoyl peroxide are often used separately to treat acne with some effectiveness

Pulsethera’s technology, in combination with benzoyl peroxide, has been demonstrated to kill C. acnes in vitro